A Phase Ia and Ib Dose-Ranging Study to Assess the Safety, Pharmacokinetics, and Antiviral Efficacy of PPI-383 in Healthy Adults and Hepatitis C Patients
Phase of Trial: Phase I
Latest Information Update: 30 Nov 2015
Price : $35 *
At a glance
- Drugs PPI 383 (Primary)
- Indications Hepatitis C
- Focus Adverse reactions
- Sponsors Presidio Pharmaceuticals
- 25 Nov 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 20 Oct 2015 Planned End Date changed from 1 Oct 2015 to 1 Nov 2015 as reported by ClinicalTrials.gov record.
- 20 Oct 2015 Planned primary completion date changed from 1 Sep 2015 to 1 Jul 2015 as reported by ClinicalTrials.gov record.